Serotonin blockade protects against early microvascular constriction following atherosclerotic plaque rupture

Eur J Pharmacol. 2004 Feb 13;486(1):85-9. doi: 10.1016/j.ejphar.2003.12.001.

Abstract

Early microvascular constriction following atherosclerotic plaque rupture may be mediated via serotonin and/or endothelin-1. Atherosclerotic lesions in the rabbit hindlimb underwent plaque rupture, resulting in a rapid reduction of distal flow (7.1+/-0.7 ml/min pre-rupture versus 3.6+/-0.6 ml/min post-rupture, P<0.001) and a rise in distal microvascular resistance (10.5+/-0.9 mm Hg min/ml pre-rupture versus 23.5+/-3.5 mm Hg min/ml post-rupture, P=0.01). Distal microvascular resistance remained elevated following endothelin-1 receptor antagonism and control vehicle, but normalised after serotonin receptor antagonism with ritanserin (10.5+/-0.9 mm Hg min/ml pre-rupture versus 22.2+/-6.0 mm Hg min/ml post-endothelin-1 receptor antagonism [P<0.05] versus 21.6+/-6.2 mm Hg min/ml post-control vehicle [P<0.05] versus 11.6+/-2.0 mm Hg min/ml post-ritanserin [P=NS]). Early antagonism of serotonin receptors protects against distal microvascular constriction following atherosclerotic plaque rupture.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Arteriosclerosis / drug therapy*
  • Arteriosclerosis / physiopathology
  • Blood Flow Velocity / drug effects
  • Disease Models, Animal
  • Iliac Artery / drug effects
  • Iliac Artery / physiology
  • Indans / pharmacology
  • Microcirculation / drug effects
  • Microcirculation / physiology
  • Rabbits
  • Receptors, Serotonin, 5-HT2 / physiology
  • Ritanserin / pharmacology*
  • Ritanserin / therapeutic use
  • Rupture / drug therapy
  • Rupture / physiopathology
  • Serotonin 5-HT2 Receptor Antagonists*
  • Vasoconstriction / drug effects*
  • Vasoconstriction / physiology

Substances

  • Indans
  • Receptors, Serotonin, 5-HT2
  • Serotonin 5-HT2 Receptor Antagonists
  • 1H-Indene-2-carboxylic acid, 1-(1,3-benzodioxol-5-yl)-3-(2- (carboxymethoxy)-4-methoxyphenyl)-2,3-dihydro-5-propoxy-, (1S,2R,3S)-
  • Ritanserin